Table 4. Prognostic factors in patients with AC/ASC histology.
| Characteristics | Univariate analysis of PFS | Multivariate analysis of PFS | |||
|---|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | ||
| Age (yr) | ≤50 | 1 | 1 | ||
| >50 | 1.87 (0.58–8.25) | NS | 5.14 (1.12–32.60) | 0.035* | |
| Treatments | RT | 1 | 1 | ||
| CCRT | 1.86 (0.68–5.92) | NS | 2.95 (0.67–16.10) | NS | |
| FIGO stage | IIB–IIIA | 1 | 1 | ||
| IIIB–IVA | 1.06 (0.73–5.59) | NS | 1.60 (0.36–7.19) | NS | |
| PLN meta | Negative | 1 | 1 | ||
| Positive | 1.40 (0.39–4.05) | NS | 0.13 (0.01–1.08) | NS | |
| Tumor size (mm) | ≤40 | 1 | 1 | ||
| >40 | 11.20 (2.22–203.00) | 0.001* | 15.70 (1.53–458.00) | 0.018* | |
| Duration of RT (day) | ≤55 | 1 | 1 | ||
| >55 | 0.77 (0.12–2.81) | NS | 0.35 (0.04–1.92) | NS | |
| Pretreatment Hb (g/dL) | <11.0 | 1 | 1 | ||
| ≥11.0 | 1.36 (0.43–5.98) | NS | 0.86 (0.08–8.79) | NS | |
| Response to treatment | CR | 1 | 1 | ||
| Non-CR | 6.15 (2.04–19.40) | 0.002* | 11.40 (1.78–101.00) | 0.010* | |
AC, adenocarcinoma; ASC, adenosquamous carcinoma; CCRT, concurrent chemoradiotherapy; CI, confidence interval; CR, complete response; FIGO, International Federation of Gynecology and Obstetrics; HR, hazard ratio; NS, not significant; PFS, progression-free survival; PLN, popliteal lymph node; RT, radiotherapy.
*p-value is less than 0.05.